Skip to main content
. 2022 Dec 26;62(1):101–112. doi: 10.1007/s40262-022-01191-6

Fig. 4.

Fig. 4

Observed and model-predicted percentage of patients with ulcerative colitis (UC) who achieved efficacy endpoints at maintenance Week 52. The dots and error bars represent the median and 95% confidence interval (CI) of observed NRI response by quartile of upadacitinib Cavg; solid lines and shaded areas represent the median and 95% CIs for model-predictions; boxplots represent the spread of exposure for different doses. NRI, nonresponder imputation